Glaucoma News and Research

Latest Glaucoma News and Research

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced additional positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

10 Nov 2010

Researchers study drug's ability to restore retinal health in eyes of diabetic patients

One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people.

10 Nov 2010

TransTech Pharma, High Point receive $1.96 million grants under QTDP program

TransTech Pharma, Inc. and High Point Pharmaceuticals, LLC. today announced that they have been awarded cash grants totaling $1.96 million under the U.S. Government's Qualifying Therapeutic Discovery Project program.

8 Nov 2010

FIP Annual Meeting to improve global health through advances in pharmaceutical sciences

Global health crises like the recent cholera outbreak in Haiti emphasize the need for new ways to prevent deadly diseases from becoming widespread in developing countries. International experts and scientists will present research ranging from developing a freeze-dried cholera vaccine to new methods of delivering medicines to underserved populations at the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in New Orleans, La., Nov. 13-18.

4 Nov 2010

Acton submits Manufacturing Supplement to FDA for AEROSPAN Inhalation Aerosol

Acton Pharmaceuticals, Inc. today announced that it has submitted to the U.S. Food and Drug Administration (FDA), a Manufacturing Supplement to the previously approved AEROSPAN Inhalation Aerosol NDA.

4 Nov 2010

QLT third quarter sales decreases 12.9% to $20.5 million

QLT Inc. today reported financial results for the third quarter ended September 30, 2010. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

3 Nov 2010

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

AstraZeneca announced today that results from TITAN, a 12-week study of SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol in African American patients with moderate to severe persistent asthma, showed significant improvement in lung function for patients taking SYMBICORT compared with those using budesonide alone.

3 Nov 2010

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced it has entered into a supply and distribution agreement with Watson Laboratories, Inc. to distribute an authorized generic version of CONCERTA (methylphenidate HCl extended-release tablets).

3 Nov 2010

ISTA third quarter net revenue increases 31% to $42.0 million

ISTA Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2010. Third quarter 2010 net revenues were $42.0 million, an increase of 31% from the third quarter of 2009.

3 Nov 2010

TriRima shows positive result in food-induced cardiovascular effects associated with MAO inhibitors

CeNeRx BioPharma, Inc., today announced that a new formulation of TriRima, its lead agent for treatment resistant depression, showed excellent safety in a study designed to test whether it is free of the food-induced cardiovascular effects associated with conventional MAO inhibitors.

2 Nov 2010

Allergan third quarter diluted loss per share increases to $2.21

Allergan, Inc. today announced operating results for the quarter ended September 30, 2010. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on December 1, 2010 to stockholders of record on November 10, 2010.

1 Nov 2010

CONCERTA improves handwriting performance in children with ADHD: Study

Data presented today at a major medical meeting include findings that demonstrate improved handwriting performance in children with Attention Deficit Hyperactivity Disorder (ADHD) when taking CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) compared to placebo.

30 Oct 2010

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Shire plc the global specialty biopharmaceutical company, today announced results from a Phase 2 signal finding study of Vyvanse(R) [lisdexamfetamine dimesylate (or SPD489)] in patients who have had residual symptoms of depression following treatment with LEXAPRO(escitlopram) for Major Depressive Disorder (MDD).

29 Oct 2010

ACADIA and BLS enter agreement to conclude pimavanserin collaboration

ACADIA Pharmaceuticals Inc. today announced that it has entered into an agreement with Biovail Laboratories International SRL ("BLS"), a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc., pursuant to which ACADIA and BLS have agreed to conclude their previously established collaboration to develop and commercialize pimavanserin in the United States and Canada.

29 Oct 2010

deCODE genetics publishes high resolution recombination map of human genome in Nature journal

Scientists from deCODE genetics today publish in Nature the highest resolution recombination map of the human genome yet developed. Recombination is the reshuffling of the genome that occurs in the formation of eggs and sperm: we inherit one version of each chromosome from each of our parents, and create novel blends of the two that we pass on to our offspring.

28 Oct 2010

Diabetes threatens the eyesight of many unsuspecting Americans

Diabetes causes more new cases of legal blindness among working-age Americans than any other disease. If diabetics are monitored regularly by their ophthalmologist, this vision loss is almost always avoidable. Yet, tragically, more than half of all people living with diabetes do not get the recommended annual dilated eye exam. As the number of people with Type 2 diabetes rises in the U.S., the CDC projects that the number of adults with diabetic retinopathy will double by the year 2050. Yet 90 percent of diabetic eye disease can be prevented simply by proper regular examinations and treatment and by controlling blood sugar.

27 Oct 2010

Study observes interaction between HLA-C and ERAP1 genes in psoriasis

Genetic variants associated with increased susceptibility to psoriasis are reported in five papers published online this week in Nature Genetics. Psoriasis is a chronic and recurrent skin disease, and one of the most prevalent autoimmune diseases, with a global prevalence of 2-3%.

19 Oct 2010

AAO-MEACO Meeting highlights data on glaucoma risk in people with migraine, innovative uses of digital technology

Data on glaucoma risk in people with migraine and on innovative uses of mobile, digital technology are featured in today's Scientific Program, to be presented at the 2010 American Academy of Ophthalmology (AAO) - Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting.

18 Oct 2010

FDA approves ISTA's sNDA for BROMDAY ophthalmic anti-inflammatory drug

ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.

18 Oct 2010

2010 AAO-MEACO meeting focuses on genetic medicine

Genetic medicine is the focus of two presentations at today's Scientific Program of the 2010 American Academy of Ophthalmology (AAO) Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting. The AAO-MEACO meeting is in session October 16 through 19 at McCormick Place, Chicago. It is the largest, most comprehensive ophthalmic education conference in the world.

18 Oct 2010

Glaucoma News and Research

Latest Glaucoma News and Research

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

Researchers study drug's ability to restore retinal health in eyes of diabetic patients

TransTech Pharma, High Point receive $1.96 million grants under QTDP program

FIP Annual Meeting to improve global health through advances in pharmaceutical sciences

Acton submits Manufacturing Supplement to FDA for AEROSPAN Inhalation Aerosol

QLT third quarter sales decreases 12.9% to $20.5 million

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

ISTA third quarter net revenue increases 31% to $42.0 million

TriRima shows positive result in food-induced cardiovascular effects associated with MAO inhibitors

Allergan third quarter diluted loss per share increases to $2.21

CONCERTA improves handwriting performance in children with ADHD: Study

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

ACADIA and BLS enter agreement to conclude pimavanserin collaboration

deCODE genetics publishes high resolution recombination map of human genome in Nature journal

Diabetes threatens the eyesight of many unsuspecting Americans

Study observes interaction between HLA-C and ERAP1 genes in psoriasis

AAO-MEACO Meeting highlights data on glaucoma risk in people with migraine, innovative uses of digital technology

FDA approves ISTA's sNDA for BROMDAY ophthalmic anti-inflammatory drug

2010 AAO-MEACO meeting focuses on genetic medicine

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Glaucoma News and Research

Latest Glaucoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in